Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    "Hepatocellular carcinoma (fibrolamellar variant)"
Show Display Options
Rank Status Study
1 Recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
2 Active, not recruiting Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Conditions: Fibrolamellar Carcinoma;   Fibrolamellar Liver Cancer
Interventions: Drug: everolimus;   Drug: letrozole plus leuprolide;   Drug: combination of everolimus, letrozole and leuprolide
3 Terminated Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
Conditions: Hepatocellular Carcinoma;   Fibrolamellar Hepatocellular Carcinoma
Intervention: Drug: Sutent
4 Recruiting Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Conditions: Fibrolamellar Hepatocellular Carcinoma;   Hepatocellular Carcinoma (Fibrolamellar Variant);   Hepatocellular Carcinoma
Interventions: Procedure: living related donor partial liver transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow transplant from same donor;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: mycophenolate mofetil;   Drug: Prednisone;   Drug: Antithymocyte globulin;   Drug: fludarabine

Study has passed its completion date and status has not been verified in more than two years.